Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CPS1 | P31327 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 8/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759008 | 0.88 | HPGD (0.52) | HPGDTSHRMAPTCPS1SMN1; SMN2 | |
| SCHEMBL3759056 | 0.83 | HDAC8 (0.53) | TSHRDPP4CYP3A4KDM4EPARP1 | |
| SCHEMBL3757028 | 0.82 | HPGD (0.56) | HPGDTSHRMAPTSMN1; SMN2KDM4E | |
| SCHEMBL3753422 | 0.79 | TSHR (0.68) | TSHRMAPTSMN1; SMN2KDM4E | |
| SCHEMBL3764255 | 0.79 | HPGD (0.47) | HPGDTSHRMAPTCPS1DPP4 | |
| SCHEMBL3753660 | 0.79 | EPHX2 (0.52) | TSHRDPP4CYP3A4 | |
| SCHEMBL2820382 | 0.77 | SERPINE1 (0.47) | DPP4CYP3A4SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL2818775 | 0.76 | SERPINE1 (0.46) | DPP4CYP3A4SMN1; SMN2KDM4E | |
| SCHEMBL3764229 | 0.75 | HCRTR1 (0.44) | SMN1; SMN2KDM4E | |
| SCHEMBL12882367 | 0.75 | HCRTR1 (0.47) | HPGDCYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842696-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-30 | — | — | US | claimed |
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-03 | — | — | US | claimed |
| US-7842696-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-30 | — | — | US | disclosed |
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-03 | — | — | US | disclosed |
| WO-2008157844-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | HPGD 503/4885TSHR 4601/4885MAPT 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.